东阿阿胶：10月24日召开董事会会议

Group 1 - The core point of the article is that Dong'e Ejiao held its 13th meeting of the 11th board of directors on October 24, 2025, to review the proposal for the third quarter report of 2025 [1] - For the first half of 2025, Dong'e Ejiao's revenue composition was as follows: pharmaceutical industry accounted for 97.88%, donkey breeding and trade accounted for 1.11%, and other industries accounted for 1.01% [1] - As of the report date, Dong'e Ejiao's market capitalization was 30.8 billion yuan [1] Group 2 - The article also mentions that Chinese innovative drugs have sold overseas authorizations worth 80 billion USD this year, highlighting the hot secondary market in biomedicine [1] - A dialogue with Lu Gang, a partner at Chuangdongfang Investment, indicates that while the secondary market is thriving, the primary market is facing challenges in fundraising [1]